MyAmyloidosisTeam

Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) that acts as a TTR stabilizer, similar to tafamidis. However, while it has been studied for treating hATTR amyloidosis with cardiomyopathy, it has not received FDA approval for this use. Doctors may prescribe it off-label, meaning it's being used for a purpose Show Full Answer

Diflunisal is a nonsteroidal anti-inflammatory drug (NSAID) that acts as a TTR stabilizer, similar to tafamidis. However, while it has been studied for treating hATTR amyloidosis with cardiomyopathy, it has not received FDA approval for this use. Doctors may prescribe it off-label, meaning it's being used for a purpose different from its FDA-approved indication. In contrast, tafamidis and tafamidis meglumine (Vyndaqel) are the only FDA-approved TTR stabilizers. Clinical studies have shown that tafamidis significantly improves survival rates, especially when started early in the disease course. For example, after 10 years of treatment, nearly 96 percent of people with early-onset hATTR familial amyloid polyneuropathy who were treated with tafamidis were still alive.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

hATTR Amyloidosis Treatments: Comparing Your Options

What’s the Life Expectancy With hATTR Amyloidosis?